Product Images Levetiracetam Extended-release
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Levetiracetam Extended-release NDC 35208-031 by Intellipharmaceutics Corp., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Description: This is a medication labeled "Levetiracetam" that comes in a tabit form with each tabit containing 500mg of levelracetam USP. It is advised for the pharmacist to dispense it with a resistant container and closure to protect it from children. The medication is for prescription only and dosage recommendation can be found in the package insert. The medication should be stored in a cold, dry place between 15-30°C. The manufacturer of the medication is "Itelipramaceutics Corp" located in Toronto, Canada. It comes with an NDC code of 35208-031-60 and is for once-daily dosing. A medication guide is included with the medication.*
This is a medication called Levetiracetam which is available in tablet form with a strength of 750mg. The tablets are film-coated and come in a bottle with child-resistant closure. The usual dosage is mentioned in the package insert. The medication should be stored at room temperature between 15-30°C. This medication should be kept out of reach of children. The tablets are manufactured by the company Ilipramaceutics Corp located in Toronto, Canada, and come in a bottle containing 60 tablets. A medication guide should be dispensed to each patient along with the tablets. The Lot number and expiration date are also provided.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.